This study is testing a new medicine called ALXN1920 for people with a kidney disease called membranous nephropathy.
About the study
The aim of this study is to see if ALXN1920 is safe and whether it can help reduce kidney damage. People in the study will receive either the study medicine or a placebo (a treatment with no active medicine), as well as their usual treatment. The study involves regular hospital visits over about 9 months, including weekly injections, blood and urine tests, and health checks.
Anticipated enrolment close date: June 2027
Who can take part
You may be eligible to participate if you:
- are 18 years or older
- have a kidney disease called membranous nephropathy
- are not on dialysis
- are receiving usual treatment for your kidney condition or are not pregnant or breastfeeding
- are not taking part in another clinical trial
- are able to attend regular hospital visits
What's involved for you
- around 29 hospital visits over about 9 months
- weekly injections under the skin for around 6 months (study medicine or placebo)
- regular health checks, including weight, blood pressure and heart rate
- blood tests at many visits
- urine tests, including some 24 hour urine collections
- heart tests (ECG) using stickers placed on the chest
- questionnaires about your health
- one follow up visit about 4 weeks after treatment finishes
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.